# A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr

Source: https://onco.cc/trials/nct05451810/  
OnCo record `nct05451810` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Epcoritamab in diffuse large b-cell lymphoma and follicular lymphoma, run by Genmab, active and no longer recruiting.

## Summary

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma is a phase 2 interventional study registered as NCT05451810 by Genmab, with 184 participants planned, started 2022-08-17 and due to reach its primary completion in 2027-03. Interventions recorded: Epcoritamab. Conditions listed: Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05451810
- Phase: 2
- Setting: A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient Setting
- Sponsor: Genmab
- Enrolled: 184

## Sources

- ClinicalTrials.gov NCT05451810: https://clinicaltrials.gov/study/NCT05451810

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Epcoritamab](https://onco.cc/drugs/epcoritamab/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct05451810.json